SEARCH

SEARCH BY CITATION

References

  • 1
    Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clinics North Am 1995; 24:475 507.
  • 2
    Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde K-H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448 55.
  • 3
    Lee E. Split ileostomy in the treatment of Crohn’s disease of the colon. Ann R Coll Surg Eng 1975; 56:94 102.
  • 4
    D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262 7.
  • 5
    Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91:328 32.
  • 6
    Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. NEJM 1997; 337:1029 35.
  • 7
    Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997; 113:383 9.
  • 8
    Thayer WR, Coutu JA, Chiodini RJ, Van Kruiningen HJ, Merkal RS. Possible role of Mycobacteria in inflammatory bowel disease. Mycobacterial antibodies in Crohn’s disease. Dig Dis Sci 1984; 29:1080 5.
  • 9
    Kobayashi K, Brown WR, Brennan PJ, Blaser MJ. Serum antibodies to mycobacterial antigens in active Crohn’s disease. Gastroenterology 1988; 94:1404 11.
  • 10
    Brunello F, Pera A, Martini S et al. Antibodies to Mycobacterium paratuberculosis in patients with Crohn’s disease . Dig Dis Sci 1991; 36:1741 5.
  • 11
    Rowbotham DS, Howdle PD, Trejdosiewicz LK. Peripheral cell mediated immune response to mycobacterial antigens in inflammatory bowel disease. Clin Exp Immunol 1995; 102:456 61.
  • 12
    Targan SR & Murphy LK. Clarifying the causes of Crohn’s. Nat Med 1995; 1:1241 3.
  • 13
    Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde K-H, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26:934 8.
  • 14
    Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253 61.
  • 15
    Kühn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 1993; 75:263 74.
  • 16
    Strober W & Ehrhardt RO. Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell 1993; 78:203 95.
  • 17
    Rath HC, Herfarth HH, Ikeda JS et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human B2 microglobulin transgenic rats. J Clin Invest 1996; 98:945 53.
  • 18
    Sartor RB. The role of endogenous luminal bacteria and bacterial products in the pathogenesis of experimental enterocolitis and systemic inflammation. In: KagnoffMF, KiyonoH, eds. Essentials of mucosal immunology. New York: Academic Press, 1996:307 20.
  • 19
    Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694 702.
  • 20
    Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109:1344 67.
  • 21
    Cebra JJ, Jiang H-Q, Sterzl J, Tlaskalova-Hogenova H. The role of mucosal microbiota in the development and maintenance of the mucosal immune system. In: OgraPL, MesteckyJ, LammME, StroberW, BienenstockJ, eds. Mucosal immunology. New York: Academic Press, 1998: 267 80 .
  • 22
    Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265:1237 40.
  • 23
    Elson CO, Beagley KW, Sharmanov AT et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996; 157:2174 85.
  • 24
    Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183:2605 16.
  • 25
    Pierre P, Denis O, Bazin H, Mbongolo Mbella E, Vaerman JP. Modulation of oral tolerance to ovalbumin by cholera toxin and its B subunit. Eur J Immunol 1992; 22:3179 82.
  • 26
    Elson CO & Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984; 133:2892 7.
  • 27
    Lycke N. The mechanisms of cholera toxin adjuvanticity. Res Immunol 1997; 148:504 20.
  • 28
    Hornquist E & Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol 1993; 23:2136 43.
  • 29
    Michetti P, Porta N, Mahan MJ, Slauch JM, Mekelalanos JJ, Blum AL, Kraehenbuhl JP, Neutra MR. Monoclonal immunoglobulin A prevents adherence and invasion of polarized epithelial cell monolayers by Salmonella typhimurium. Gastroenterology 1994; 107:915 23.
  • 30
    Madsen KL, Foyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116:1107 14.
  • 31
    Lycke N, Karlsson U, Sjolander A, Magnusson KE. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol 1991; 33:691 8.
  • 32
    Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sodium sulphate-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107:1643 52.
  • 33
    Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius AC. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4( + )-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996; 45:181 91.
  • 34
    Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238 49.
  • 35
    Rath HC, Schultz M, Dieleman LA, Li F, Kolbl H, Falk W, Scholmerich J, Sartor RB. Selective vs. broad spectrum antibiotics in the prevention and treatment of experimental colitis in two rodent models. Gastroenterology 1998; 114:A1067.
  • 36
    Gorbach SL, Nahas L, Lerner PI, Weinstein L. Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology 1967; 53:845 55.
  • 37
    Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun 1995; 63:3904 13.
  • 38
    Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176:1355 64.
  • 39
    Friedman A & Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 1994; 91:6688 92.
  • 40
    Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18:335 43.